Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.69 |
| ▸ | PPARD | Q03181 | 11/20 | 0.55 |
| ▸ | PPARG | P37231 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333235 | 0.93 | PPARA (0.67) | PPARAPPARDPPARGMEN1MAPT | |
| SCHEMBL6328138 | 0.91 | PPARA (0.56) | PPARAPPARDPPARGSTAT3 | |
| SCHEMBL6328831 | 0.90 | PPARA (0.57) | PPARAPPARDPPARGMEN1MAPT | |
| SCHEMBL6330385 | 0.88 | PPARA (0.53) | PPARAPPARDPPARGSTAT3 | |
| SCHEMBL6329127 | 0.85 | PPARA (0.56) | PPARAPPARDPPARGMEN1MAPT | |
| Trifluoroacetic Acid SCHEMBL6333105 | 0.84 | DGAT1 (0.51) | PPARAMEN1MAPTKMT2A | |
| SCHEMBL6325756 | 0.83 | PPARA (0.54) | PPARAPPARDPPARGMEN1MAPT | |
| SCHEMBL6328294 | 0.83 | PPARA (0.49) | PPARAPPARDPPARGMEN1MAPT | |
| SCHEMBL6325562 | 0.82 | PPARA (0.55) | PPARAPPARDPPARGMEN1MAPT | |
| SCHEMBL6329096 | 0.81 | PPARA (0.56) | PPARAPPARDPPARGMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014805-A1 | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014805-A1 | Phenyl substituted 5-membered nitrogen containing heterocycles for the treatment of obesity | GPR119, EGLN3, PC | PPARA 49/4885PPARD 55/4885PPARG 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.